Bibliographic information
Recommendation
The World Health Organization (WHO) recommends treatment with IL-6 receptor blockers (tocilizumab or sarilumab) for patients with severe or critical COVID-19 infection.
Recommended in favor
Strong
Certainty of evidence
Moderate
Also Featured In
This recommendation also appears in the following guidelines:
Therapeutics and COVID-19: living guideline, 24 September 2021.
Therapeutics and COVID-19. Living guideline. 7 December 2021
Therapeutics and COVID-19: living guideline, 14 January 2022.
Therapeutics and COVID-19: living guideline, 3 March 2022.
Therapeutics and COVID-19: living guideline, 22 April 2022.
Therapeutics and COVID-19: living guideline, 14 July 2022.
Therapeutics and COVID-19: living guideline, 16 September 2022.
Therapeutics and COVID-19: living guideline, 13 January 2023.
Therapeutics and COVID-19: living guideline, 10 November 2023.
Therapeutics and COVID-19: living guideline, August 2025